Comparative Pharmacology
Head-to-head clinical analysis: QUINORA versus TAMBOCOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUINORA versus TAMBOCOR.
QUINORA vs TAMBOCOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Quinora (quinidine) is a Class Ia antiarrhythmic agent that blocks sodium channels, prolonging the action potential duration and effective refractory period. It also exhibits anticholinergic and negative inotropic effects.
Class Ic antiarrhythmic agent; blocks sodium channels, slowing conduction velocity and prolonging refractoriness in cardiac tissues.
325 mg orally every 4 to 6 hours as needed, not to exceed 4 g/day.
For atrial fibrillation/flutter: 50 mg orally every 12 hours; may increase by 50 mg every 4 days up to 300 mg/day. For life-threatening ventricular arrhythmias: 100 mg orally every 12 hours; increase by 50 mg every 4 days up to 400 mg/day.
None Documented
None Documented
5-7 hours; prolonged in hepatic impairment (up to 12-15 hours) and in elderly patients.
Terminal elimination half-life: 12–27 hours (mean 20 hours); prolonged to 58 hours in heart failure or renal impairment (CrCl < 35 mL/min).
Primarily hepatic (biliary) excretion into feces (~80-90%); renal excretion of unchanged drug accounts for ~10-20%.
Renal: 85% (30% unchanged, 55% as inactive metabolites); Fecal: 5%; Biliary: negligible.
Category C
Category C
Antiarrhythmic Agent
Antiarrhythmic Agent